Category: Treatment


Biomarkers: What They Are, Why They Matter, and Where They are Going

22 July 2021 In Allies & Partnerships, Science, Treatment

The melanoma treatment field has been rewarded recently with an abundance of riches. But all these exciting new treatment options for patients can also create complexity and confusion. Fortunately, help is on the way in the form of biomarkers — molecular or cellular indicators for whether a patient is likely to respond or is currently responding to their therapy, or whether they are likely to have a recurrence of their cancer.

Read More


2021 AACR and ASCO Melanoma Highlights

By Marc Hurlbert, PhD, MRA Chief Executive Officer | 29 June 2021 In News, Science, Treatment

Over the last few months, thousands of scientists and physicians from around the globe gathered virtually for two of the largest cancer research conferences – AACR and ASCO. Melanoma research advances were showcased at both events and it’s an exciting time with numerous presentations of clinical trials for new melanoma treatments. Here we highlight some of the most exciting results from both conferences.

Read More


New Immunotherapy Drugs Targeting LAG-3 Show Great Promise

By Kristen Mueller, PhD | 23 June 2021 In News, Science, Treatment

Researchers presented a series of highly encouraging clinical trial results at the recent American Society for Clinical Oncology (ASCO) annual meeting that suggest that new drugs targeting the protein LAG-3 – developed by BMS and Regeneron – may be an important addition to the current treatment arsenal.

Read More


Averting and Treating Immune-related Adverse Events Associated with Checkpoint Immunotherapies

14 June 2021 In Science, Treatment

Checkpoint inhibitors are therapies that empower the immune system to kill cancer cells. However, sometimes immune-related adverse events (irAE) can also occur as a result. To help overcome this challenge, MRA has issued a number of research grants, including some in partnership with the American Cancer Society (ACS) and the Society for Immunotherapy of Cancer (SITC), to support an array of approaches.

Read More


Advancing Melanoma Research in Times of Uncertainty

By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 9 June 2021 In Allies & Partnerships, Melanoma Stories, Policy, Prevention, Science, Treatment

Each year, the annual MRA Scientific Retreat brings hundreds of people from across the melanoma research ecosystem together to exchange ideas, report on scientific progress, celebrate achievements, and mourn the losses. In these ways, the 2021 Retreat was no different.

Read More


Separating Hope From Hype in Melanoma Research

By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 4 June 2021 In Science, Treatment

In the last decade alone 13 therapeutic approaches have earned FDA approval giving patients, families, and clinicians new tools to treat melanoma. But there can be a fine line between hope and hype, especially today when news — both true and inflated — travels instantly via the internet and social media.

Read More


Firming the Foundation: Pathology, Rare Melanomas, and Moving the Field Forward

By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 21 May 2021 In Science, Treatment

When Dr. Priyadharsini Nagarajan talks about her work at MD Anderson Cancer Center, her energy and excitement could light up any room. That’s because Dr. Nagarajan – a pathologist who specializes in skin (called a ‘dermatopathologist’) – sees her work as critical to creating a firm foundation for all subsequent...

Read More


Melanoma Research Alliance Announces $8.1 million in Research Awards

By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 27 April 2021 In News, Prevention, Science, Treatment

The Melanoma Research Alliance, the largest non-profit funder of melanoma research, is proud to announce $8.1 million in funding for 34 new research awards. The awards, issued on the cusp of Melanoma Awareness Month, provide critical funding to address urgent unmet needs in melanoma.

Read More


A New Treatment Approach in the Arsenal: Neoadjuvent Therapy

23 April 2021 In Allies & Partnerships, News, Science, Treatment

Surgery is the backbone of melanoma treatment and is curative for the vast majority of patients with localized melanoma. However, even if surgery successfully removes all detectible traces of tumor tissue, some patients will still experience a melanoma relapse. Can neoadjuvant therapy, an experimental approach, reduce the risk of recurrence?

Read More


Against the Odds: Racing for Melanoma Research

19 April 2021 In Allies & Partnerships, Melanoma Stories, Treatment

Patrick O’Neill along with his four closest college friends and fellow Boat Racing, LLC members, find themselves in a very implausible position: first-time horse owners heading to the Kentucky Derby—horseracing’s pinnacle event.

Read More


Login

×